Exelixis Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (26)

Latest Posts

About This Stock More About This Stock
Biotech Bear Market: But Is It Time To Start Trading?
Article By: Rod Raynovich
Sunday, November 11, 2018 11:31 PM EST
The NASDAQ is down 1.6% and the Russell 2000 is down 1.8%, killing hopes of a continued Post-Election rally. The biotech sector is for experienced traders only. Healthcare still looks good overall with the XLV down only 0.29% at $92.95.
In this article: BMY, MRK, RHHBY, IBB, IMMU, LGND, QQQ, EXEL, NBIX, AMRN, IJR, XLV, ICPT, ABBV, SRPT, XNCR, LOXO, XLRN, IONS, REGN, CELG, GILD, VRTX, ASH, TSRO
Read
Trump Announces Plan To Reign In Drug Prices And Pharma Stocks Rally
Article By: Zacks Investment Research
Sunday, May 13, 2018 11:37 AM EST
President Trump unveiled his plan to control US drug prices. Stock prices of the biggest drug companies briefly declined, only to reverse course and ended the day broadly higher. The reason? The plan doesn’t seem to be “taking them on” at all.
In this article: LLY, MRK, AMGN, EXEL, ABBV
Read
Bull Of The Day: Exelixis
Article By: Kevin Cook
Friday, May 11, 2018 9:55 AM EST
Unique among small biotech companies, EXEL is a profitable mid-cap cancer fighter with projected 58% revenue growth and 68% EPS growth this year.
In this article: EXEL
Read
Exelixis, Roche Slide After Colon Cancer Drug Fails To Meet Primary Study Goal
Article By: The Fly
Thursday, May 10, 2018 12:50 PM EST
Shares of Exelixis and partner Roche are under pressure this morning after the companies announced that the Phase 3 IMblaze370 trial did not achieve statistical-significance on the primary efficacy endpoint.
In this article: RHHBY, EXEL Also: BMY, MRK, ARRY
Read
4 Biotech Stocks To Watch In The New Year
Article By: Zacks Investment Research
Sunday, January 7, 2018 5:23 PM EST
Biotech companies are continuously working on bringing innovative new treatments to market, and there could be significant catalysts in the coming quarters in the form of important product approvals as well as major data read-outs.
In this article: EBS, GSK, MDCO, XOMA, EXEL, NVS, MLNT
Read

PARTNER HEADLINES

Latest Tweets for $EXEL

No tweets yet!